Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, ...
November 17 2016 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced that scientists from MD Anderson Cancer Center will be
presenting data from a preclinical study evaluating poziotinib in
lung cancer at the 17th International Association for the Study of
Lung Cancer (IASLC) World Conference on Lung Cancer taking place in
Vienna, Austria, December 4-7, 2016.
“Poziotinib has shown promising efficacy in preclinical models
of non-small cell lung cancer (NSCLC) with exon 20 insertion
mutations,” said John Heymach, MD, PhD, Chairman, Professor, and
David Bruton Junior Chair in Cancer Research, Department of
Thoracic/Head and Neck Medical Oncology, The University of Texas MD
Anderson Cancer Center. “Tumors with these mutations have generally
not been responsive to approved EGFR inhibitors, and there is an
unmet need for better therapies for these patients. Computational
modeling suggests that poziotinib may overcome steric hindrance of
the drug binding pocket induced by the exon 20 insertion mutations.
Based on these results, we are in the process of initiating a Phase
2 study in lung cancer that we plan to start in the near
future.”
“Poziotinib has already shown promising data in breast cancer,
and we are excited that it may now have application in lung cancer
as well," said Rajesh C. Shrotriya, MD, Chairman and Chief
Executive Officer of Spectrum Pharmaceuticals. “Lung cancer is the
leading cause of cancer deaths in the world. Due to the mutations
in the genes, lung cancer often becomes unresponsive to treatments.
Patients who have exon 20 insertion mutations have few options, if
any. We look forward to working closely with MD Anderson Cancer
Center to continue development of this drug in this area of unmet
medical need.”
17th IASLC World Conference on Lung
Cancer
Abstract Title:
Poziotinib overcomes de novo resistance of
EGFR exon 20 insertion mutations in NSCLC
Oral Presentation Schedule:
December 7, 2016 Session “Novel Strategies in Targeted Therapies”
Abstract Link:
http://library.iaslc.org/search-speaker?search_speaker=44257
About Poziotinib
Poziotinib is a novel, oral pan-HER inhibitor that irreversibly
blocks signaling through the Epidermal Growth Factor Receptor
(EGFR, HER) Family of tyrosine-kinase receptors, including HER1
(erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4), and importantly,
also HER receptor mutations; this, in turn, leads to the inhibition
of the proliferation of tumor cells that overexpress these
receptors. Mutations or overexpression/amplification of EGFR family
receptors have been associated with a number of different cancers,
including non-small cell lung cancer (NSCLC), breast cancer, and
gastric cancer.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161117005306/en/
Spectrum PharmaceuticalsShiv KapoorVice President, Strategic
Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2024 to May 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From May 2023 to May 2024